Aberdeen Group
JNCE

Aberdeen Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Aberdeen Group’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-23,735
Closed -$291K – 1045
2021
Q1 		$291K Buy
23,735
+8,486
+56% +$92.9K ﹤0.01% 957
2020
Q4 		$114K Buy
+15,249
New +$119K ﹤0.01% 952

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aberdeen Group's JNCE Position: Q2 2021 in Review

Aberdeen Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2021, closing a stake of 23,735 shares — an estimated $291K sold.

Aberdeen Group first reported a position in JNCE in Q4 2020 and held it in 2 quarters. The position peaked at $291K in Q1 2021. 130 funds tracked by Wall St. Rank hold JNCE as of Q2 2021.

  • Aberdeen Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Aberdeen Group sold 23,735 Jounce Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $291K.
  • Aberdeen Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Aberdeen Group's Jounce Therapeutics, Inc. Common Stock position peaked at $291K in Q1 2021.
  • 130 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Aberdeen Group's 13F filing for Q2 2021, filed 10 Aug 2021.